Erasca to Present at the Jefferies Global Healthcare Conference

Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company targeting RAS/MAPK pathway-driven cancers, will participate in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York.

Rhea-AI Summary

Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company targeting RAS/MAPK pathway-driven cancers, will participate in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York.

Management will join a fireside chat on June 3, 2026 at 3:10 p.m. ET, with a live and archived webcast on Erasca.com/events.

Argus May 27 session

+8.43% close to close Open Argus

Details

News Market Reaction – ERAS

On May 27, the day this news came out, ERAS closed 8.43% above the previous close.

Data tracked by StockTitan Argus for the May 27 session.

Market Context

On May 27, the day this news came out, the stock closed 8.4% above the previous close. A strong posi...

Analysis

On May 27, the day this news came out, the stock closed 8.4% above the previous close. A strong positive reaction aligns with Erasca’s pattern of meaningful moves around visibility events and clinical updates. Prior positive ERAS‑0015 data on April 27, 2026 saw a sharp but contrary move, underscoring volatility. With an active $500,000,000 shelf and at‑the‑market capacity, further capital raises remain possible, which could influence sustainability of gains after conference-related enthusiasm fades.

Key Figures

Fireside chat time: 3:10 pm Eastern Time Replay availability: 30 days

Fireside chat time

3:10 pm Eastern Time

Jefferies Global Healthcare Conference on June 3, 2026

Replay availability

30 days

Archived webcast access period at Erasca.com/events

Historical Context

5 past events · Latest: May 11

5 events

1. May 11

   Earnings and pipeline

   24h Move

   -0.6%

   Q1 2026 results with widened net loss and RAS franchise investment.

2. May 11

   Clinical collaboration

   24h Move

   +3.2%

   Merck collaboration to evaluate ERAS-0015 with KEYTRUDA in solid tumors.

3. May 06

   Investor conference

   24h Move

   +9.1%

   Bank of America health care conference fireside chat and investor meetings.

4. Apr 27

   Phase 1 data

   24h Move

   -48.3%

   Positive preliminary Phase 1 dose-escalation data for ERAS-0015 in KRAS tumors.

5. Apr 27

   Data webcast

   24h Move

   -10.9%

   Conference call and webcast to discuss preliminary ERAS-0015 Phase 1 data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ras/mapk pathway, webcast

2 terms

ras/mapk pathway medical

"therapies for patients with RAS/MAPK pathway-driven cancers"

A cellular signaling route that acts like a chain of command inside cells to tell them when to grow, divide, or die; when parts of this RAS/MAPK pathway are stuck “on,” it can drive uncontrolled cell growth that leads to cancer. Investors care because drugs, tests, or diagnostics that target or measure this pathway can become valuable products, affect drug approval chances, and change a company’s revenue or risk profile much like fixing a critical production line in a factory.

webcast technical

"A live audio webcast of the event will be available online"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY. Management will participate in a fireside chat on Wednesday, June 3, 2026, at 3:10 pm Eastern Time and will also participate in one-on-one investor meetings.

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Erasca (NASDAQ: ERAS) present at the Jefferies Global Healthcare Conference in 2026?

Erasca will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 3:10 p.m. Eastern Time. According to Erasca, management will participate in a fireside chat and hold one-on-one investor meetings during the event.

What type of event will Erasca (ERAS) host at the Jefferies Global Healthcare Conference?

Erasca management will participate in a fireside chat at the Jefferies Global Healthcare Conference. According to Erasca, the session is scheduled for June 3, 2026, at 3:10 p.m. Eastern Time, alongside additional one-on-one investor meetings.

How can investors access Erasca's June 3, 2026 Jefferies conference webcast?

Investors can access a live audio webcast of Erasca’s Jefferies conference appearance at Erasca.com/events. According to Erasca, an archived replay of the June 3, 2026 fireside chat will remain available on the same site for 30 days after the webcast.

Will a replay of Erasca (ERAS) at the 2026 Jefferies Global Healthcare Conference be available?

Yes, a replay of Erasca’s Jefferies Global Healthcare Conference fireside chat will be available. According to Erasca, the archived audio webcast will be accessible for 30 days following the live June 3, 2026 event at Erasca.com/events.

Where is the 2026 Jefferies Global Healthcare Conference featuring Erasca being held?

The 2026 Jefferies Global Healthcare Conference featuring Erasca is being held at the Marriott Marquis in New York, NY. According to Erasca, its management will join a fireside chat there and conduct one-on-one meetings with investors.

What does Erasca focus on as a clinical-stage company presenting at Jefferies 2026?

Erasca is a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers. According to Erasca, its mission centers on discovering, developing, and commercializing targeted therapies, which it will highlight while engaging investors at the Jefferies Global Healthcare Conference.